Coherus Oncology (CHRS) Stock: Buy, Sell, or Hold?
CHRS - Coherus Oncology, Inc. Common Stock
$1.01
-0.04 (-3.81%)
▼
5d:
+2.02%
30d:
-13.68%
90d:
-30.82%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
10d
Get Alerted When CHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CHRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CHRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CHRS is currently trading at $1.01, which is considered oversold relative to its 30-day fair value range of $1.02 to $1.27.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $0.94, while resistance sits at $1.09. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.75 (+667.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CHRS is in a strong uptrend. Immediate support is located at $0.94, while resistance sits at $1.09. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.75 (+667.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.02 -
$1.27
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 667.3% below Wall St target ($7.75)
- NEUTRAL: Bottoming setup forming (50/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$1.02 -
$1.27
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.94
Resistance Level
$1.09
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.60
Wall Street Target
$7.75
(+667.3%)
Revenue Growth (YoY)
39.5%
Earnings Growth (YoY)
-75.5%
Profit Margin
-259.4%
Share & Embed Analysis
Last updated: October 25, 2026 11:27 AM ET
Data refreshes hourly during market hours. Next update: 12:27 PM
Data refreshes hourly during market hours. Next update: 12:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$107 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 58 HOLD |
